Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension

Tsung-Ming Lee, Chien Chang Chen, Hsiu Nien Shen, Nen Chung Chang

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660±352 to 1006±316 s (P

Original languageEnglish
Pages (from-to)497-505
Number of pages9
JournalClinical Science
Volume116
Issue number6
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Pravastatin
Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Exercise
Placebos
Endothelin-1
Lung

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • Dyspnoea
  • Endothelin-1 (ET-1)
  • Exercise capacity
  • Pulmonary hypertension
  • Statin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. / Lee, Tsung-Ming; Chen, Chien Chang; Shen, Hsiu Nien; Chang, Nen Chung.

In: Clinical Science, Vol. 116, No. 6, 03.2009, p. 497-505.

Research output: Contribution to journalArticle

@article{e20f09cea38440eaa3fc305b00569852,
title = "Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension",
abstract = "PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52{\%} from 660±352 to 1006±316 s (P",
keywords = "Chronic obstructive pulmonary disease (COPD), Dyspnoea, Endothelin-1 (ET-1), Exercise capacity, Pulmonary hypertension, Statin",
author = "Tsung-Ming Lee and Chen, {Chien Chang} and Shen, {Hsiu Nien} and Chang, {Nen Chung}",
year = "2009",
month = "3",
doi = "10.1042/CS20080241",
language = "English",
volume = "116",
pages = "497--505",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension

AU - Lee, Tsung-Ming

AU - Chen, Chien Chang

AU - Shen, Hsiu Nien

AU - Chang, Nen Chung

PY - 2009/3

Y1 - 2009/3

N2 - PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660±352 to 1006±316 s (P

AB - PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660±352 to 1006±316 s (P

KW - Chronic obstructive pulmonary disease (COPD)

KW - Dyspnoea

KW - Endothelin-1 (ET-1)

KW - Exercise capacity

KW - Pulmonary hypertension

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=65549089130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549089130&partnerID=8YFLogxK

U2 - 10.1042/CS20080241

DO - 10.1042/CS20080241

M3 - Article

VL - 116

SP - 497

EP - 505

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 6

ER -